Item 5. Market for Registrant’s Common Equity
ITEM 5. MARKET FOR THE COMPANY'S COMMON EQUITY, RELATED STO CKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market and Stockholder Information
Our common stock has been listed on The NASDAQ Global Select Market under the symbol “ENTA” since March 21, 2013 and we had 17 stockholders of record as of November 12, 2024. The following table shows the high and low sales price for our common stock as reported by The NASDAQ Global Select Market for the quarterly periods in the fiscal years ended September 30, 2024 and 2023:
Fiscal 2024
High
Low
First Quarter
$
11.07
$
8.08
Second Quarter
$
17.76
$
9.24
Third Quarter
$
17.80
$
11.28
Fourth Quarter
$
17.24
$
9.90
Fiscal 2023
High
Low
First Quarter
$
54.20
$
39.60
Second Quarter
$
62.06
$
38.16
Third Quarter
$
41.45
$
19.91
Fourth Quarter
$
22.15
$
11.03
We have never declared or paid cash dividends on our common stock, and we do not expect to declare or pay any cash dividends for the foreseeable future.
58
Performance Graph (1)
The following graph shows a comparison from September 30, 2019 through September 30, 2024 of cumulative total return on assumed investments of $100.00 in cash in each of our common stock, the NASDAQ Composite Index and the NASDAQ Biotechnology Index. Such returns are based on historical results and are not intended to suggest future performance. Data for the NASDAQ Composite Index and the NASDAQ Biotechnology Index assume reinvestment of dividends.
COMPARISON OF FIVE YEARS CUMULATIVE TOTAL RETURN
Among Enanta Pharmaceuticals, Inc., the NASDAQ Composite Index,
and the NASDAQ Biotechnology Index
(1) This performance graph shall not be deemed to be “soliciting material” or to be “filed” with the SEC for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section, and shall not be deemed incorporated by reference into any filing of Enanta Pharmaceuticals, Inc. under the Securities Act of 1933, as amended.
ITEM 6. [R ESERVED]
59
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.